Person:

Pelletier-Galarneau, Matthieu

Background: Mitochondrial membrane potential (ΔΨm) arises from normal function of the electron transport chain. Maintenance of ΔΨm within a narrow range is essential for mitochondrial function. Methods for in vivo measurement of ΔΨm do not exist. We use 18F-labeled tetraphenylphosphonium (18F-TPP+) to measure and map the total membrane potential, ΔΨT, as the sum of ΔΨm and cellular (ΔΨc) electrical potentials. Methods: Eight pigs, five controls and three with a scar-like injury, were studied. Pigs were studied with a dynamic PET scanning protocol to measure 18F-TPP+ volume of distribution, VT. Fractional extracellular space (fECS) was measured in 3 pigs. We derived equations expressing ΔΨT as a function of VT and the volume-fractions of mitochondria and fECS. Seventeen segment polar maps and parametric images of ΔΨT were calculated in millivolts (mV). Results: In controls, mean segmental ΔΨT = -129.4±1.4 mV (SEM). In pigs with segmental tissue injury, ΔΨT was clearly separated from control segments but variable, in the range -100 to 0 mV. The quality of ΔΨT maps was excellent, with low noise and good resolution. Measurements of ΔΨT in the left ventricle of pigs agree with previous in in-vitro measurements. Conclusions: We have analyzed the factors affecting the uptake of voltage sensing tracers and developed a minimally invasive method for mapping ΔΨT in left ventricular myocardium of pigs. ΔΨT is computed in absolute units, allowing for visual and statistical comparison of individual values with normative data. These studies demonstrate the first in vivo application of quantitative mapping of total tissue membrane potential, ΔΨT.

Momcilovic et al1 report mitochondrial metabolism differences amongst various mouse lung cancer subtypes, as measured by positron emission tomography (PET) and a voltage-sensitive tracer. They describe their experiments as measurements of mitochondrial membrane potential, ΔΨm, and suggest that they might be used as a non-invasive biomarker to guide the delivery of complex I inhibitors in cancer. Contrary to their claims, Momcilovic et al did not measure membrane potential in an absolute sense, instead relying on an empirical endpoint, namely the percent dose per gram of the tracer in tumor to that in heart, which only partially depends on ΔΨm. Despite the biomedical significance of their findings, their work represents critical methodological misunderstandings and omissions about the underlying basis for application of voltage sensing tracers which could ultimately hinder the successful clinical translation of the technique.